Loading…
Lobbying Income
$316K
Filings
17
Unique Clients
1
Active Period
2014–2017
Registrant-reported income from clients on LDA filings
Largest clients by registrant-reported income
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Quarterly Financial Report Reauthorization Act
2016 · fourth_quarter · Client: ELI LILLY AND COMPANY
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Client expense: — · Firm income: —
Matched citations: H.R. 3116
Quarterly Financial Report Reauthorization Act
2016 · fourth_quarter · Client: ELI LILLY AND COMPANY
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Client expense: — · Firm income: —
Matched citations: H.R. 3116
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Client expense: — · Firm income: —
Matched citations: H.R. 9
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Client expense: — · Firm income: —
Matched citations: S. 1137
Alaska Native Claims Settlement Improvement Act of 2016
2016 · fourth_quarter · Client: ELI LILLY AND COMPANY
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Client expense: — · Firm income: —
Matched citations: S. 3004
Alaska Native Claims Settlement Improvement Act of 2016
2016 · fourth_quarter · Client: ELI LILLY AND COMPANY
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Client expense: — · Firm income: —
Matched citations: S. 3004
Quarterly Financial Report Reauthorization Act
2016 · third_quarter · Client: ELI LILLY AND COMPANY
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Client expense: — · Firm income: $12,120
Matched citations: H.R. 3116
Quarterly Financial Report Reauthorization Act
2016 · third_quarter · Client: ELI LILLY AND COMPANY
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Client expense: — · Firm income: $12,120
Matched citations: H.R. 3116
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Client expense: — · Firm income: $12,120
Matched citations: H.R. 9
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Client expense: — · Firm income: $12,120
Matched citations: S. 1137
Alaska Native Claims Settlement Improvement Act of 2016
2016 · third_quarter · Client: ELI LILLY AND COMPANY
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Client expense: — · Firm income: $12,120
Matched citations: S. 3004
Alaska Native Claims Settlement Improvement Act of 2016
2016 · third_quarter · Client: ELI LILLY AND COMPANY
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Client expense: — · Firm income: $12,120
Matched citations: S. 3004
Quarterly Financial Report Reauthorization Act
2016 · second_quarter · Client: ELI LILLY AND COMPANY
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Client expense: — · Firm income: $8,160
Matched citations: H.R. 3116
Quarterly Financial Report Reauthorization Act
2016 · second_quarter · Client: ELI LILLY AND COMPANY
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Client expense: — · Firm income: $8,160
Matched citations: H.R. 3116
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Client expense: — · Firm income: $8,160
Matched citations: H.R. 9
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Client expense: — · Firm income: $8,160
Matched citations: S. 1137
Alaska Native Claims Settlement Improvement Act of 2016
2016 · second_quarter · Client: ELI LILLY AND COMPANY
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Client expense: — · Firm income: $8,160
Matched citations: S. 3004
Alaska Native Claims Settlement Improvement Act of 2016
2016 · second_quarter · Client: ELI LILLY AND COMPANY
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Client expense: — · Firm income: $8,160
Matched citations: S. 3004
Quarterly Financial Report Reauthorization Act
2016 · first_quarter · Client: ELI LILLY AND COMPANY
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Client expense: — · Firm income: $16,240
Matched citations: H.R. 3116
Quarterly Financial Report Reauthorization Act
2016 · first_quarter · Client: ELI LILLY AND COMPANY
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Client expense: — · Firm income: $16,240
Matched citations: H.R. 3116
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Client expense: — · Firm income: $16,240
Matched citations: H.R. 9
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Client expense: — · Firm income: $16,240
Matched citations: S. 1137
Alaska Native Claims Settlement Improvement Act of 2016
2016 · first_quarter · Client: ELI LILLY AND COMPANY
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Client expense: — · Firm income: $16,240
Matched citations: S. 3004
Alaska Native Claims Settlement Improvement Act of 2016
2016 · first_quarter · Client: ELI LILLY AND COMPANY
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Client expense: — · Firm income: $16,240
Matched citations: S. 3004
Quarterly Financial Report Reauthorization Act
2015 · fourth_quarter · Client: ELI LILLY AND COMPANY
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Client expense: — · Firm income: —
Matched citations: H.R. 3116
Source: Senate LDA